Literature DB >> 9689095

In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.

G P Robertson1, F B Furnari, M E Miele, M J Glendening, D R Welch, J W Fountain, T G Lugo, H J Huang, W K Cavenee.   

Abstract

Gross genetic lesions of chromosome 10 occur in 30-50% of sporadic human melanomas. To test the functional significance of this observation, we have developed an in vitro loss of heterozygosity approach in which a wild-type chromosome 10 was transferred into melanoma cells, where there was selection for its breakage and regional deletion to relieve its growth suppressive effects. The overlap of these events was at band 10q23, the site of the recently isolated PTEN/MMAC1 tumor suppressor gene, suggesting it as a potential target. Although the gene was expressed in the parental cells, both of its chromosomal alleles contained truncating mutations. In vitro loss of heterozygosity resulted in loss of the chromosomally introduced wild-type PTEN/MMAC1, and ectopic expression of the gene caused cell growth suppression. Thus, this approach identified PTEN/MMAC1 as a target in malignant melanoma and may provide an alternative means to localizing tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9689095      PMCID: PMC21353          DOI: 10.1073/pnas.95.16.9418

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Fluorescence in situ hybridization with DNA probes.

Authors:  B Trask; D Pinkel
Journal:  Methods Cell Biol       Date:  1990       Impact factor: 1.441

2.  Suppression of tumorigenicity in Wilms tumor by the p15.5-p14 region of chromosome 11.

Authors:  S F Dowdy; C L Fasching; D Araujo; K M Lai; E Livanos; B E Weissman; E J Stanbridge
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

3.  Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression.

Authors:  B E Weissman; P J Saxon; S R Pasquale; G R Jones; A G Geiser; E J Stanbridge
Journal:  Science       Date:  1987-04-10       Impact factor: 47.728

4.  Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.

Authors:  S K Kim; L K Su; Y Oh; B L Kemp; W K Hong; L Mao
Journal:  Oncogene       Date:  1998-01-08       Impact factor: 9.867

5.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.

Authors:  W K Cavenee; T P Dryja; R A Phillips; W F Benedict; R Godbout; B L Gallie; A L Murphree; L C Strong; R L White
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

Review 6.  Human cancer syndromes: clues to the origin and nature of cancer.

Authors:  E R Fearon
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

7.  Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas.

Authors:  A Richmond; R Fine; D Murray; D H Lawson; J H Priest
Journal:  J Invest Dermatol       Date:  1986-03       Impact factor: 8.551

8.  Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia.

Authors:  A H Parmiter; G Balaban; W H Clark; P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1988-02

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Genetic origin of mutations predisposing to retinoblastoma.

Authors:  W K Cavenee; M F Hansen; M Nordenskjold; E Kock; I Maumenee; J A Squire; R A Phillips; B L Gallie
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

View more
  27 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

3.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 4.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 5.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

6.  Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.

Authors:  Pedro R Cutillas; Asim Khwaja; Mariona Graupera; Wayne Pearce; Severine Gharbi; Mike Waterfield; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

Review 7.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

8.  Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.

Authors:  Ying Hang; Yong-Chen Zheng; Yan Cao; Qing-Shan Li; Yu-Jie Sui
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

9.  Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.

Authors:  Lawrence N Kwong; Lynda Chin
Journal:  Cancer Res       Date:  2014-01-22       Impact factor: 12.701

10.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.